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Abstract
Purpose: We aimed to investigate the safety, tolerability, and systemic diffusion of a single escalating dose of
XG-102 (a 31-D-amino-acid peptide inhibiting JNK pathway activation), administered subconjunctivally in the
treatment of post-surgery or post-trauma intraocular inflammation.
Methods: This is a dose-escalating, tolerance Phase Ib study. Twenty patients with post-surgery or post-
traumatic intraocular inflammation were assigned to 1 of the 4 dose escalating (45, 90, 450, or 900mg XG-102)
groups of 5 patients each. Patients were evaluated at 24, 48 h, 8, and 28 days following the administration of
XG-102, including laboratory tests, standard eye examinations, vital signs, and occurrence of adverse events. A
single plasma quantification of XG-102 was performed 30min after administration, according to previous
pharmacokinetics studies performed on volunteers.
Results: A total of 17 non-serious adverse events, considered unrelated to the study treatment, were reported for
10 patients. The adverse event incidence was not related to the drug dose. All patients experienced a decrease in
intraocular inflammation as of 24 h post-administration and this decrease was sustained up to 28 days thereafter.
No patient required local injection or systemic administration of corticoids following the administration of XG-
102. XG-102 was undetectable in the first 3 dose groups. In the fourth-dose group (900mg) the XG-102 plasma
levels were above the limit of detection for 3 patients and above the limit of quantification for 1 patient.
Conclusions: In this first clinical trial using XG-102, administered as a single subconjunctival injection as
adjunct therapy, in patients with recent post-surgery or post-trauma intraocular inflammation is safe and well
tolerated. Further studies are required to evaluate its efficacy.
Introduction
JNK pathway activation has been identified as a keyplayer in inflammatory reactions, which is associated with
various diseases affecting the cardiovascular, neuronal, hepato-
biliary, digestive, joint, hearing, and respiratory tissues.1–5 In-
flammation occurs as a result of various cellular activities
(proliferation, differentiation, survival, and transformation) being
mediated by mitogen-activated protein kinase and some intra-
cellular signaling molecules.6,7 Intracellular JNK cascade can be
activated by many different signaling molecules, such as geno-
toxic, osmotic, hypoxic, or oxidative stress molecules, but also
by pro-inflammatory cytokines, such as tumor necrosis factor-a
and interleukin-1b.6,7 The regulation of the complex JNK path-
way is important regarding the arising expression of growth
factors, cell surface receptors, cytokines, inflammatory mole-
cules, degradative enzymes, or cell adhesionmolecules by cells.5
To control the JNK-driven inflammatory processes, spe-
cific JNK inhibitors are being developed and studied. The
JNK-inhibiting function associated with the XG-102 peptide
(peptide in a dextrogyre configuration: enhanced resistance
to proteases) has increased its clinical interest for treating
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inflammatory processes when looking at the documented ef-
ficacy in different disease groups, such as neuronal,8–25 car-
diovascular,26 digestive,27 and hearing disorders.28–30 As of
yet, limited data are available concerning the efficacy of this
compound in the treatment of intraocular inflammation but
one of the main advantages could be its potential to act locally
thus limiting any potential systemic side effects resulting from
nonspecific JNK pathway inhibition. It was recently demon-
strated in a rat intraocular model of inflammation (endotoxin-
induced uveitis) that JNK pathway is activated and that local
administration of XG-102 significantly reduced the ocular
inflammation score, inflammatory cell infiltration, and induc-
ible nitric oxide synthase expression in rat eyes,31 suggesting
that XG-102 could have potential efficacy in the treatment of
intraocular inflammation in humans.
Postoperative induced intraocular inflammation causes dis-
comfort, such as miosis, pain, and hyperemia, and impairs vi-
sual acuity. Corticosteroids or nonsteroidal anti-inflammatory
drugs (NSAIDs) are commonly used to reduce postoperative
intraocular inflammation.1–3 However, both of the treatments
are associatedwith well-known side effects. Corticosteroids are
associated with increased intraocular pressure (IOP), cataract
progression, and systemic side effects due to an important
blood diffusion.32 The observed side effects for NSAIDs when
administered topically include stinging or burning sensation
and conjunctival hyperemia. In addition, both corticosteroid
and NSAID therapies require administration several times per
day over a period for at least 14 days, and often for 21 days.
Hence the development of alternative treatments for such
conditions that have similar efficacy in reducing intraocular
inflammation but that have less side effects and for which the
dosing regimen is shorter in duration would be an attractive
alternative to treating postoperative intraocular inflammation.
The objective of this trial was to investigate the safety and
tolerability of a subconjunctival administration of XG-102
[single escalating dose (45, 90, 450, and 900mg XG-102)] in
patients with post-surgery or post-traumatic intraocular in-
flammation. In addition, plasma quantification of XG-102
measured 30min post-dosing was evaluated.
Methods
Study design
This was an open-label study designed to assess the safety
and tolerability of a single subconjunctival injection of XG-
102 administered for post-surgery or post-traumatic intra-
ocular inflammation in single, escalating doses of 45, 90,
450, or 900 mg. XG-102 was administered as adjunct therapy
to the usual treatment/management [corticosteroid eye drops
(Dexafree, Thea or Chibrocadron, Thea) administered 3–
4 times per day for 28 days] for post-surgery or post-trau-
matic intraocular inflammation. No immediate postoperative
subconjunctival administration of glucocorticoids was per-
formed but instead in case needed, because of the severity of
the case or the complexity of the surgery, it was considered
as requested by the surgeon, and it was replaced by XG-102
subconjunctival injection.
Subjects used
Briefly, men or postmenopausal women, aged ‡ 18 years,
who had provided written informed consent, were eligible to
participate if they had undergone recent ocular surgery or
trauma and were diagnosed with acute inflammation of the
anterior and/or posterior segment defined as anterior chamber
cell grade ‡ 2+ and/or anterior chamber flare ‡ 2+ and/or
vitreous haze ‡ 2+ . The main exclusion criteria included
open wound of the eyeball; presence of any surgical or
medical condition that, in the judgment of the investigator,
could have interfered with the study conduct; and a history of
serious adverse reaction or hypersensitivity to protein-type
drugs or to vaccines or currently treated for seasonal allergies.
Patient safety was overseen by the Data Safety Monitor-
ing Board (DSMB). Within each dose level, only 1 patient
was treated at the same time and there was a minimum of
24 h before the next patient was recruited. During the 24-h
period, the tolerability of XG-102 was assessed. Upon
completion of a dose group, the DSMB reviewed the pa-
tients’ data and escalation to the next dose group was con-
ditional on receiving their recommendation to do so. There
was minimally a 7-day break between the end of one dose
group and the start of the next dose group.
Prior to the start of patient recruitment, the trial was ap-
proved by the ethics committee and regulatory authorities.
The studywas designed and carried out in accordance with the
provisions of the Declaration of Helsinki, ICH, GCP require-
ments of the European Union, and the applicable French laws
and regulations. The study was recorded on the Clinical Trial
Directory of the national agency for drug safety (France)
after the Eudravigilance registration (EudraCT number 2011-
000171-14). Written informed consent was obtained before
any trial-related procedure was commenced for any 1 patient.
Patient number was sufficient for the specific objectives;
however, no statistical-power-based calculation was made.
Interventions
After eligibility had been ascertained and the baseline visit
performed, the subconjunctival injection of XG-102 was
performed. The XG-102 vials were conserved at - 20C in a
temperature-controlled freezer. For each patient the vial was
removed from the freezer and thawed at room temperature at
least 1 h before the preparation of the syringe. A total volume
of 250mL XG-102 was administered for each patient and was
followed between 5 and 15min thereafter with the instillation
of the standard treatment eye drops (Dexafree, unpreserved
dexamethasone sodium phosphate or Chibrocadron, dexa-
methasone sodium phosphate+ neomycin administered 3–4
times per day for 28 days).
Pre- and post-administration assessments
Patients were examined at baseline and then at 24h, 48 h, 8
days, and 28 days after administration ofXG-102. Examinations
performed at these visits included standard eye examinations,
visual acuity (ETDRS), slit lamp, ophthalmic fundus assess-
ment, ocular motility (finger test), IOP measurement, eye
photography, vital signs, laboratory tests [chemistry: aspartate-
amino-transferase (ASAT), alanine-amino-transferase (ALAT),
alkaline phosphatase, C-reactive protein (CRP), creatine kinase
(CK), total proteins, glucose, creatinine, total bilirubin, calcium,
serum albumin, sodium, potassium, gamma-glutamyl transfer-
ase and lactate dehydrogenase, and urea; hematology: hemo-
globin (Hb), hematocrit (HCT), full white cell count, and
coagulation assays, and assessment of the occurrence of adverse
events.
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Blood sampling for XG-102 quantification was performed
30min after its administration according to previous phar-
macokinetic studies in humans. Analyte concentration in
plasma samples was determined by a validated HPLC-MS/
MS (high-performance liquid chromatography, tandem
mass spectrometry) assay with a lower limit of quantifica-
tion (LLOQ) of 10 ng/mL and a limit of detection (LOD) of
5 ng/mL. The blood samples obtained during the study were
collected into Li-Heparin tubes and stored frozen before the
XG-102 quantification. Main samples were analyzed while
back-up specimens were kept frozen for eventual repeat
analysis.
Sample size and statistical analysis
As this was a Phase Ib study, no formal sample size
calculations were performed. The sample size of 20 patients
(5 per dose group) was considered sufficient to meet the
objectives of the trial. The Statistical Analysis Plan was
completed prior to database lock.
The incidence of events was documented per dose group
with the total number of events, the number of patients with
serious adverse events, and the corresponding percentage of
patients.
Results
Subject disposition
Twenty patients (20 eyes) were successively recruited
between June 1, 2011 and November 30, 2011, in the de-
partment of ophthalmology of Hoˆtel-Dieu in Paris. The
main demographic data are summarized in Table 1. Due to
the limited number of patients included by group, ages were
not perfectly balanced.
Safety and tolerability
No serious adverse events were reported. A total of 17
adverse events (6 during the first 24 h and 11 between 24 h
and 28 days) were reported for 10 patients and the adverse
event incidence was similar between the 4 dose groups, and
particularly not related to the drug dose. In total, 6 adverse
events that occurred at Visit 1 after the subconjunctival
injection of XG-102 were reported for 4 patients—3 in the
second-dose group and 1 in the fourth group (which was the
highest dose). In total, 11 adverse events were reported for
8 patients as of Visit 1 and up to Visit 4. Two AEs were
reported for 2 patients in dose Group 1 and 2 events were
reported for 1 patient in dose Group 2, while 4 adverse
events were reported for 2 patients in dose Group 3 and 3
events were reported for 3 patients in dose Group 4. The
overview of the reported adverse events, sorted by System
Organ Class, is presented by dose group in Table 2. Clini-
cally relevant (as assessed by the investigator) out-of-range
laboratory test results were reported as adverse events and
no such events were considered by the investigator to be
related to study treatment. The relation to the treatment was
estimated upon analysis with the patient pretreatment con-
dition and the estimated effects of the administrated drug.
Importantly, the investigator was not aware of the treatment
dose when making this analysis.
Functional results
Concerning the ophthalmology examinations, as can be
seen in Figs. 1 and 2, for each of the dose groups, there was a
reduction in intraocular inflammation, as assessed by anterior
chamber cell grade and cell flare. This reduction was apparent
as of 24 h after the administration of XG-102 as an adjunct
therapy and was sustained up to day 28 thereafter (see Figs. 1
and 2). Due to the fact that the protocol was not designed to
assess efficacy but only safety, it is not possible to conclude
on any efficacy of the drug but we can at least conclude that
the tested drug did not induce any inflammation.
Pharmacokinetics
For patients who received either 45, 90, or 450mg XG-
102, the plasma concentration of XG-102 was undetectable
(ie, below the LOD, LOD = 5 ng/mL). Plasma quantification
of XG-102 demonstrated no systemic passage of XG-102
after subconjunctival injection of 45, 90, or 450 mg while,
for 3 out of 5 patients administered the 900mg dose, the
LOD was exceeded but dosing remained below the limit of
quantification and, for 1 patient, a detectable and quantifi-
able plasmatic value was observed. Based on the results of
the plasma quantification of XG-102, the systemic passage
Table 1. Main Baseline Characteristics and Demographics
Dose Group 1
(45 mg) (n = 5)
Dose Group 2
(90mg) (n = 5)
Dose Group 3
(450 mg) (n = 5)
Dose Group 4
(900 mg) (n = 5)
Demographics
Age (years) 56.2 – 6.1 59.6 – 8.6 53.2 – 15.6 57 – 16.8
Male 4 (80%) 4 (80%) 2 (40%) 2 (40%)
Caucasian 4 (80%) 5 (100%) 3 (60%) 4 (80%)
Indications
Surgery 4 (80%) 5 (100%) 5 (100%) 5 (100%)
Cataract extraction 2 0 0 1
Retinal surgery 1 5 5 1
Silicon oil extraction 1 0 0 1
Cataract extraction + retinal surgery 0 0 0 2
Trauma 1 (20%) 0 (0%) 0 (0%) 0 (0%)
Data are number of patients (%) or mean– standard deviation.
n, number of patients.
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Table 2. Adverse Event Listing
MedDRA term
Relation to study
treatment Severity
Dose Group 1 (45 mg)
Investigations Blood potassium decreased Unclassified Mild
Blood lactate dehydrogenase increased Unclassified Mild
Dose Group 2 (90 mg)
Eye disorders Pigment dispersion syndrome None Mild
Ocular hypertension Unclassified Mild
Investigations Neutrophil count increased None Mild
White blood cell count increased None Mild
Alanine aminotransferase increased None Mild
Aspartate aminotransferase increased None Mild
C-reactive protein increased None Mild
Dose Group 3 (450mg)
Eye disorders Intraocular pressure increased None Mild
Investigations Alanine aminotransferase increased None Mild
Blood alkaline phosphatase increased None Mild
Gamma-glutamyltransferase increased None Mild
Dose Group 4 (900mg)
Eye disorders Ocular hypertension None Mild
General disorders and administration
site conditions
Injection site pain Unclassified Moderate
Investigations Blood creatinine phosphokinase increased None Moderate
Vascular disorders Hypertension None Mild
MedDRA, medical dictionary for regulatory activities.
FIG. 1. Anterior chamber cells–median values: median
anterior chamber cell level in XG-102-treated groups (45,
90, 450, and 900 mg) over time. For all patients in all dose
groups combined, there was a reduction in the intraocular
inflammation as of Visit 1 (inflammation being related to the
anterior chamber cell score). The reduction in inflammation
was sustained and continued up to the last visit at 28 days.
Time 0= baseline value. Actual time points when visits were
performed. Planned time/date relative to start of the sub-
conjunctival injection: V1= planned at 24 h - min/max
range visit performed relative to planned time: - 5 h 45min
to + 1 h 15min; V2= planned at 48 h - min/max range visit
performed relative to planned time: - 5 h 45min to + 3 h
30min; V3= 8 days - min/max range visit performed rela-
tive to planned date: - 2 days to + 1 day; V4= 28 days -min/
max range visit performed relative to planned time: - 8 days
to + 37 days.
FIG. 2. Anterior chamber flare–median values: median
anterior chamber flare level in XG-102-treated groups (45,
90, 450, and 900mg) over time. For all patients in all dose
groups combined, there was a reduction in the intraocular
inflammation as of Visit 1 (inflammation being related to the
anterior chamber flare score). The reduction in inflammation
was sustained and continued up to the last visit at 28 days.
Time 0 = baseline value. Actual time points when visits were
performed. Planned time/date relative to start of the sub-
conjunctival injection: V1 = planned at 24 h - min/max
range visit performed relative to planned time: - 5 h 45min
to + 1 h 15min; V2 = planned at 48 h - min/max range visit
performed relative to planned time: - 5 h 45min to + 3 h
30min; V3= 8 days - min/max range visit performed rela-
tive to planned date: - 2 days to + 1 day; V4= 28 days -min/
max range visit performed relative to planned time: - 8 days
to + 37 days.
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of XG-102 cannot be excluded and in particular in the 900-
mg-dose group, but for this dose group—given that there
were the 3 patients for whom XG-102 levels were un-
quantifiable and given that for 1 patient in this dose group,
the XG-102 quantification was just above the quantification
limit (LLOQ = 10 ng/mL, average plasma concentration)—
this could be chance finding. The clinical relevance of this
finding needs further investigation in future studies. Im-
portantly, the number of adverse events was not higher in
Group 4 (in which XG-102 was dosed in the circulation).
Discussion
This is the first study that investigates the safety, tolera-
bility, and systemic diffusion of a subconjunctival admin-
istration of a peptide inhibiting JNK pathway activation in
patients with postoperative or post-trauma intraocular in-
flammation. It is also, to the best of our knowledge, the first
study that evaluates in patients, the effects of a peptide
administered subconjunctivally for the treatment of an eye
disease. A total of 17 adverse events, all considered by the
investigator as being unrelated to XG-102, were reported for
10 patients, demonstrating, irrespective of the dose received,
a favorable local and systemic tolerance of this compound.
The limitation of the present study design is the lack of a
control group but the subconjunctival injection of vehicle,
which would have been the real control, was not accepted by
the ethical committee. Note that most of biotherapies de-
veloped in the field of ophthalmology have been first eval-
uated in human with similar study designs.33–38 Further
studies are thus required to validate the good tolerance and
to evaluate the efficacy of XG-102 for ocular use.
The decision was made to perform early sampling (30min
post-administration) of patients’ blood in order to have data on
XG-102 plasma detection. This early timing was decided
based on 2 studies of pharmacokinetics; after subconjunctival
injection (single injection or repeated daily for 10 days) was
performed in rabbits, the presence of XG-102 was not de-
tected at any time point starting 1 h post-injection. Moreover,
in a Phase I study with volunteers receiving intravenous in-
jection of XG-102, XG-102 was shown to disappear rapidly
from plasma with the geometric mean by dose of t1/2 and
mean residence time ranging from 0.36 to 0.65 h and from
0.76 to 1.02h, respectively.39 The low passage observed for 1
patient in the 900-mg group only should not be a concern as
intravenous administration of XG-102 at doses up to 80mg/kg
to healthy volunteers was well tolerated33 in a previous study
that evaluated the safety and pharmacokinetics of XG-102.
Moreover, minor systemic passage observed is to be relativ-
ized when compared with corticoids’ high systemic passage32
(98% of the administered dose) after subconjunctival injection
and their well-known side effects.
Irrespective of the dose group, all patients experienced a
reduction in intraocular inflammation, as assessed by ante-
rior chamber cell grade and cell flare. This reduction was
apparent as of 24 h after the administration of XG-102 as-
sociated with 4 drops of glucocorticosteroids and was sus-
tained up to day 28 thereafter. It cannot be ascertained to
which treatment(s) this inflammation reduction may be at-
tributed as patients were administered XG-102 in addition to
the ‘‘standard’’ postoperative anti-inflammatory treatment
that consisted of corticosteroid eye drops (Dexafree or
Chibrocadron) administered 3–4 times per day for 28 days.
However, patients included in the study presented with
complex intraocular surgery, requiring, upon surgeon esti-
mation, immediate postoperative subconjunctival glucocor-
ticoid injection.
In addition to the preclinical studies performed, currently,
exposure to XG-102 is limited to 20 patients as a sub-
conjunctival administration while Phase I studies have been
performed in 26 healthy volunteers and patients where XG-
102 was administered intravenously over a period of 60min.
In addition, more than 200 patients received XG-102 as an
intratympanic administration. XG-102 was safe and well
tolerated in these studies. Based on the promising efficacy
findings of the preclinical studies in ocular inflammation in
addition to the findings in this study, a multicenter, ran-
domized, double-blind Phase II trial was undertaken to in-
vestigate the efficacy and safety of a single subconjunctival
dose of XG-102 administered within 3 h after the end of
surgery versus the administration of dexamethasone eye
drops 4 times/day for 21 days and it was completed at the
end of 2013. Results of this study will be published soon.
The current ‘‘standard’’ treatment for post-surgery intra-
ocular inflammation is not clearly validated. In addition to
topical steroids frequently instilled, many surgeons use peri-
or intraocular glucocorticoid injections in complicated cases,
based on several studies showing their potential benefits.40–43
While being efficacious, frequent topical steroids are sub-
jected to compliance uncertainty and not without both
short- and long-term side effects, such as intraocular pressure
increase, surface healing delay, cataract, and so on. As an
alternative to peri- or intraocular steroid injection, and/or to
the repeated instillation of steroids for several weeks, a un-
ique postoperative subconjunctival injection of XG-102
could be an interesting alternative. The results of the on-
going controlled Phase II trial will provide some more in-
sights into the efficacy and safety profile of this compound.
Indeed, one of the interests of the XG-102 compound once
the efficacy will be demonstrated is the single-injection
procedure. When compared with the 3 to 4 drops, patients
should instill themselves each day during 3 to 4 weeks if they
are using corticosteroids, the compliance of the treatment in
the case of a single subconjunctival injection performed by
the surgeon will be 100%. In addition, surgeon will be much
more confident by treating the patients at the end of the
surgery and having the inflammation controlled in lieu of
expecting that the patients will follow the treatment carefully
during a month. Ultimately, at this stage of the clinical de-
velopment, none of the AEs previously known for the other
standard drugs were observed for the XG-102.
In conclusion, this study reports the tolerance of first
human subconjunctival injection of a peptide designed to
prevent activation of the JNK pathway for the treatment of
ocular inflammation. It was evaluated in postoperative oc-
ular inflammation following complex surgeries or eye
trauma and showed a good tolerance even at high doses.
Further controlled studies are being performed to demon-
strate the potential efficacy of this new class of anti-
inflammatory agents for the treatment of eye diseases.
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